Are Direct-to-Patient Access Models the Future of Pharma?
Archbow discusses the growing potential to sell directly to patients via a cash model.
Are Direct-to-Patient Access Models the Future of Pharma?
In January, Eli Lilly launched LillyDirect, a website offering access to telehealth consultations and direct home delivery of certain drugs to treat diabetes, weight loss, and migraines. In Archbow Consulting’s blog post, we discussed the growing potential to sell directly to patients via a cash model.
Meanwhile, Pfizer recently launched a similar direct-to-consumer digital platform, PfizerForAll, which aims to simplify access to healthcare. PfizerForAll helps to streamline necessary health actions, fill prescriptions, and find potential savings on Pfizer medicines. As this new model gains popularity in the market and gross-to-net pressure continues to mount, we should expect additional manufacturers to introduce these direct-to-patient models.
Archbow’s recommendations for manufacturers considering a direct-to-patient model are as relevant today as they were nearly a year ago. The following types of organizations may benefit the most from this strategic model:
- Large organizations with an extensive portfolio of drugs
- Small organizations that may be forced to engage significant stakeholders (Wholesalers, PBMs, Retail Chains, etc.) at non-sustainable rates to secure commercial success
- Any company with a pharmacy benefit product(s) that PBMs/Payers are closely monitoring and tightly managing
If you are considering a direct-to-patient model, Archbow can help. We have the right advisors with decades of commercial planning experience to improve your program design efforts, and we have recently supported similar initiatives with multiple clients.
Learn more about Team Archbow and the methodology that matters most to successful programs. Contact us today for assistance with your strategic and tactical patient support needs. Our team works seamlessly to align even the most complicated patient, product, and reimbursement journeys.
For additional insights on this topic, you may also enjoy the following:
FDA Extends Compliance Deadline for Updated DSCSA Requirements
Understanding the revised timeline for compliance with specific updated DSCSA requirements
Key Takeaways from NASP 2024
The 2024 National Association of Specialty Pharmacy (NASP) conference showcased a landscape of rapid innovation and evolving industry trends.
Digital Solutions in Patient Services
An Interview on Best Practices and Trends in 2025
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|